# A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Source: https://onco.cc/trials/nct07170644/  
OnCo record `nct07170644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nirogacestat in desmoid tumour, run by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, active and no longer recruiting.

## Summary

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) is a phase 2 interventional study registered as NCT07170644 by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, with 20 participants enrolled, started 2025-08-08 and due to reach its primary completion in 2027-05-28. Interventions recorded: Nirogacestat oral tablet. Conditions listed: Desmoid Tumor, Aggressive Fibromatosis. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07170644
- Phase: 2
- Setting: A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
- Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07170644: https://clinicaltrials.gov/study/NCT07170644

## Connected records

- cancers: [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/)
- drugs: [Nirogacestat](https://onco.cc/drugs/nirogacestat/)

---
JSON: https://onco.cc/api/v1/entities/nct07170644.json